I'm a doctor dedicated to improving health. Hacker mentality. Side hustle = clinical research. Skill = seeing dead spots. Neutral good. He/him
Jan 31, 2022 • 27 tweets • 14 min read
Can we improve how we treat cancer with stereotactic radiation? Yes, we can.
Here’s a @ClinOncology editorial with Drs. @MichaelTMilano & Alina Mihai on including clinical treatment volumes (CTVs) for microscopic disease. authors.elsevier.com/a/1eVwJ3K%7E8R… #radonc#medphys 1/
Radiation therapy (RT) can non-invasively treat microscopic disease. In curative settings, RT complements or competes w/ surgery to improve cancer care and patient outcomes.
I’ll discuss how matters using curative lung cancer and metastatic disease as examples. 2/
May 4, 2021 • 15 tweets • 15 min read
@DrAttai T2. Let’s talk now about radiation specifically for breast cancer. We’ll start w/ breast conserving therapy (BCT) – a term for breast conserving surgery w/radiation as a combined strategy with similar results to a mastectomy. #bcsm#radonc 1/@DrAttai T2. Vera Peters, whose mother had breast cancer, was a radiation oncologist advocating for smaller surgery w/RT in the 1960s-1970s. Amazing researcher and helped push us toward BCT as an option thefoldingchairhistory.com/2018/03/23/dr-…#bcsm#radonc 2/
May 4, 2021 • 19 tweets • 15 min read
@DrAttai T1. Radiation therapy (RT) is the use of ionizing radiation as way to focus subatomic energy to interact with a particular part of body in order to treat a disease. #bcsm#radonc 1/@DrAttai T1. Radiation oncology is a specialty that evolved out of radiology, which emerged as a medical field with the discovery of the x-ray in 1895. I was a history major, so I’ll share this more as a story #bcsm#radonc 2/
May 30, 2020 • 6 tweets • 5 min read
Another study of interest on systemic radiation in metastatic prostate cancer
TheraP: randomised phase II trial of 177Lu-PSMA-617 vs cabazitaxel in progressive metastatic castration resistant prostate cancer (mCRPC) #ASCO20#pcsm#radonc
H1/
ANZUP 1603 with @Prof_IanD et al evaluated radionuclide Lutetium-177 linked to prostate specific membrane antigen (177-Lu-PSMA-617) 6-8Gbq every six weeks x 6 vs. cabazitaxel 20 mg/m2 q 3 wks x 10 in men with mCRPC progressing after paclitaxel #ASCO20#pcsm
H2/
